Question

I am a breastfeeding mother and i want to know if it is safe to use IMC-C225? Is IMC-C225 safe for nursing mother and child? Does IMC-C225 extracts into breast milk? Does IMC-C225 has any long term or short term side effects on infants? Can IMC-C225 influence milk supply or can IMC-C225 decrease milk supply in lactating mothers?

IMC-C225 lactation summary

IMC-C225 is unsafe in breastfeeding
  • DrLact safety Score for IMC-C225 is 5 out of 8 which is considered Unsafe as per our analyses.
  • A safety Score of 5 indicates that usage of IMC-C225 may cause serious side effects in breastfed baby.
  • Our study of different scientific research indicates that IMC-C225 may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using IMC-C225 .
  • It is recommended to evaluate the advantage of not breastfeeding while using IMC-C225 Vs not using IMC-C225 And continue breastfeeding.
  • While using IMC-C225 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About IMC-C225 usage in lactation

Drug is cleared from the body in 7 elimination half-lives. Resuming breastfeeding is likely safe after 60 days of pumping-and-dumping (But the higher molecular weight of this recombinant monoclonal antibody and its protein structure makes it secretion into breast milk and the absortion by gastrointestinal tract unlikely).

Answer by DrLact: About IMC-C225 usage in lactation

No information is available on the clinical use of IMC-C225 during breastfeeding. Because IMC-C225 is a large protein molecule with a molecular weight of 145,782, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, IMC-C225 should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during IMC-C225 therapy and for 2 months after the last dose.

Alternate Drugs

Natalizumab(Low Risk)
Trastuzumab(Unsafe)
Secukinumab(Low Risk)
Cetuximab(Unsafe)
Nivolumab(Unsafe)
Ustekinumab(Low Risk)
Denosumab(Low Risk)
Omalizumab(Low Risk)
Ipilimumab(Unsafe)
Rituximab(Low Risk)
Abciximab(Low Risk)
Bevacizumab(Low Risk)
Basiliximab(Low Risk)
Belimumab(Low Risk)
Doxorubicin(Dangerous)
Pazopanib(Unsafe)
Cyclophosphamide(Dangerous)
Trastuzumab(Unsafe)
Cisplatin(Unsafe)
Gemcitabine(Dangerous)
Cetuximab(Unsafe)
Busulfan(Dangerous)
Erlotinib(Unsafe)
Imatinib(Unsafe)
Carboplatin(Dangerous)
Cladribine(Dangerous)
Nivolumab(Unsafe)
Paclitaxel(Dangerous)
Vinblastine(Dangerous)
Fluorouracil(Dangerous)
Dasatinib(Unsafe)
Vincristine(Dangerous)
Bleomycin(Dangerous)
Alemtuzumab(Low Risk)
Dactinomycin(Dangerous)
Nilotinib(Unsafe)
Ipilimumab(Unsafe)
Tamoxifen(Dangerous)
Vinorelbine(Dangerous)
Mitoxantrone(Dangerous)
Letrozole(Dangerous)
Dacarbazine(Dangerous)
Rituximab(Low Risk)
Exemestane(Dangerous)
Docetaxel(Dangerous)
Bevacizumab(Low Risk)
Hydroxyurea(Low Risk)
Thioguanine(Dangerous)
Etoposide(Dangerous)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.